Browsing by Author "Mier, James"

Now showing items 1-10 of 10

    • Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer 

      Zhang, Liang; Wang, Xiaoen; Bullock, Andrea; Callea, Marcella; Shah, H.; Song, Jiaxi; Moreno, K.; Visentin, B.; Deutschman, D.; Alsop, David; Atkins, M. B.; Mier, James; Signoretti, Sabina; Bhasin, Manoj; Sabbadini, R. A.; Bhatt, Rupal (American Association for Cancer Research (AACR), 2015-04-15)
      Purpose VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic RCC. However, resistance to treatment is inevitable. Identification of novel targets could lead to better ...

    • Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics 

      Frederick, Dennie T.; Salas Fragomeni, Roberto A.; Schalck, Aislyn; Ferreiro-Neira, Isabel; Hoff, Taylor; Cooper, Zachary A.; Haq, Rizwan; Panka, David J.; Kwong, Lawrence N.; Davies, Michael A.; Cusack, James C.; Flaherty, Keith T.; Fisher, David E.; Mier, James W.; Wargo, Jennifer A.; Sullivan, Ryan J. (Public Library of Science, 2014)
      While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with ...

    • Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts 

      Wang, Xiaoen; Zhang, L; O'Neill, A; Bahamon, B; Alsop, David C.; Mier, James W.; Goldberg, S. Nahum; Signoretti, Sabina; Atkins, M B; Wood, C G; Bhatt, Rupal Satish (Nature Publishing Group, 2013)
      Background: Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing tumour response in clear cell renal cell carcinoma (cRCC), but resistance to therapy is inevitable. As COX-2 is a known mediator ...

    • Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells 

      Panka, David Joel; Liu, Qingjun; Geissler, Andrew K; Mier, James W. (BioMed Central, 2013)
      Background: The studies reported herein were undertaken to determine if the angiostatic function of p53 could be exploited as an adjunct to VEGF-targeted therapy in the treatment of renal cell carcinoma (RCC). Methods: ...

    • High Dose Intermittent Sorafenib Shows Improved Efficacy Over Conventional Continuous Dose in Renal Cell Carcinoma 

      Wang, Xiaoen; Zhang, Liang; Goldberg, S. Nahum; Bhasin, Manoj; Brown, Victoria; Alsop, David C.; Signoretti, Sabina; Mier, James W.; Atkins, Michael B.; Bhatt, Rupal Satish (BioMed Central, 2011)
      Background: Renal cell carcinoma (RCC) responds to agents that inhibit vascular endothelial growth factor (VEGF) pathway. Sorafenib, a multikinase inhibitor of VEGF receptor, is effective at producing tumor responses and ...

    • Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma 

      Wang, Xiaoen; Solban, Nicolas; Khanna, Prateek; Callea, Marcella; Song, Jiaxi; Alsop, David C.; Pearsall, R. Scott; Atkins, Michael B.; Mier, James W.; Signoretti, Sabina; Alimzhanov, Marat; Kumar, Ravi; Bhasin, Manoj K.; Bhatt, Rupal S. (Impact Journals LLC, 2016)
      Treatment of metastatic renal cell carcinoma (mRCC) with agents that block signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces disease regression or stabilization in some patients; however, ...

    • Novel drugs that target the metabolic reprogramming in renal cell cancer 

      van der Mijn, Johannes C.; Panka, David J.; Geissler, Andrew K.; Verheul, Henk. M.; Mier, James W. (BioMed Central, 2016)
      Molecular profiling studies of tumor tissue from patients with clear cell renal cell cancer (ccRCC) have revealed extensive metabolic reprogramming in this disease. Associations were found between metabolic reprogramming, ...

    • Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling 

      Bhatt, Rupal; Wang, Xiaoen; Zhang, Liang; Collins, M. P.; Signoretti, Sabina; Alsop, David; Goldberg, S. N.; Atkins, Michael; Mier, James (American Association for Cancer Research (AACR), 2010-08-10)
      Treatment of metastatic renal cell cancer (RCC) with antiangiogenic agents that block vascular endothelial growth factor (VEGF) receptor 2 signaling produces tumor regression in a substantial fraction of patients; however ...

    • Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression 

      Bhasin, Manoj; Schor-Bardach, Rachel; Collins, Michael P.; Zhang, Liang; Wang, Xiaoen; Panka, David Joel; Putheti, Prabhakar; Signoretti, Sabina; Alsop, David C.; Libermann, Towia Aron; Atkins, Michael B.; Mier, James W.; Goldberg, S. Nahum; Bhatt, Rupal Satish (Public Library of Science, 2011)
      Purpose: Resistance to antiangiogenic therapy is an important clinical problem. We examined whether resistance occurs at least in part via reversible, physiologic changes in the tumor, or results solely from stable genetic ...

    • The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma 

      Wang, Xiaoen; Bullock, Andrea; Zhang, Liang; Wei, Lin; Yu, Dongyin; Mahagaokar, Kedar; Alsop, David; Mier, James; Atkins, Michael B.; Coxon, Angela; Oliner, Jon; Bhatt, Rupal (Elsevier BV, 2014-04)
      Angiopoietin 2 (Ang2) is a secreted glycoprotein upregulated at sites of angiogenesis and has been implicated in cancer neovascularization. Recent studies have suggested efficacy of combined Ang and vascular endothelial ...